Sunday, September 13, 2026

Business Technology

3 articles

BlackLine and Oracle Deploy Autonomous AI Agents Across Global Enterprise Finance Systems

BlackLine and Oracle Deploy Autonomous AI Agents Across Global Enterprise Finance Systems

BlackLine launched Agentic Financial Operations while Oracle embedded autonomous AI across its cloud ERP suite, racing to capture the enterprise finance automation market. Nearly 25% of finance leaders globally plan to increase AI spending by over 50%, even as they cut other technology budgets. The shift from rule-based automation to agentic systems marks a technical evolution in how multinational corporations handle financial close and compliance processes.

LM Salvado
Banks Deploy AI Agents in Production as Cloud Giants Fight for $89 Billion Enterprise Market

Banks Deploy AI Agents in Production as Cloud Giants Fight for $89 Billion Enterprise Market

HSBC, Wells Fargo, and Lloyds Banking Group now run AI systems handling fraud detection and customer service, signaling mainstream enterprise adoption. Snowflake's BUILD London 2026 launch targets this shift with integrated AI infrastructure. Global enterprise AI spending will reach $89 billion by 2027, with financial institutions commanding 18% of total market.

ViaNews Editorial Team
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com